Study to determine the safety and tolerability of SNDX-5613 in patients with relapsed/refractory leukemia
Full IRB Study Title:
AALL2121-A Phase 2 study of SNDX-5613 in combination with chemotherapy for patients with relapsed or refractory KMT2A-rearranged infant leukemia
IRB Study ID: 2024-010
For complete information, please visit the study at clinicaltrials.gov.
Study Sponsor:
Syndax Pharmaceuticals; Children's Oncology Group
We are currently recruiting
If you are interested in this study or have questions about your child's eligibility, please contact:
Kelly Culp: 330-543-0108
Lead Investigator
Erin Wright, MD
Director, Neuro-Oncology; Director, Shannon E. Wilkes Targeted Therapy Program; Jeffrey A. Barbour Chair for Pediatric Hematology/Oncology Research and Healing; Co-Director, Neurofibromatosis Clinic; Pediatric Neuro-Oncologist
Pediatric Brain Tumor ProgramShowers Family Center for Childhood Cancer and Blood DisordersNeurofibromatosis (NF) Clinic
